On June 7, 2018 LIDDS AB (publ) reported that it has decided on a direct share issue to Nyenburgh Holding BV, AESCAP 2.0 and BWG Invest, all being international funds that invests in closely selected European biotech- and pharma companies (Press release, Lidds, JUN 7, 2018, View Source [SID1234555913]). The raised capital will facilitate a fast acceleration of LIDDS’ development projects, including the immune-oncology field where NanoZolid based immuno-active compounds have shown very promising preclinical effects.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The direct issue of 1 180 000 shares will add approx. 21,7 MSEK to LIDDS. Nyenburgh Holding will maintain as the third largest shareholder in LIDDS and contributes with financial strength, an excellent network and expertize within the sector. AESCAP 2.0, based in Amsterdam, is a current shareholder in LIDDS that invests in next generation medicines and builds a selected portfolio of only 20 companies across Europe and the US. BWG Invest is a top ten shareholder in LIDDS and strengthens its shareholding position through this direct share issue.
The share price of 18,38 SEK is based on volume weighted average of the share price with a 5 % discount. The share issue decision is based on the shareholders authorization on LIDDS Annual Meeting on May 16, 2018.
– The directed share issue to Nyenburgh Holding, AESCAP 2.0 and BWG Invest is an important validation of the NanoZolid technology and we are very pleased to attract these funds to increase their ownership in LIDDS. The share issue adds longer term financing of the company, resources to reach key milestones in our development projects and provides additional financial strength to conduct an effective business development process, says Monica Wallter, CEO of LIDDS.
LIDDS total number of shares after the direct issue will be 23 051 188 and the share capital will amount to 1 221 712,964 SEK when the new shares are registered with the Swedish Companies Registration Office, Bolagsverket. The dilution of shares is 5,1 %.
LIDDS will with the raised capital further accelerate the exciting NanoZolid development projects with the aim to build alliances, collaborations and license agreements.
The directed share issue to Nyenburgh Holding, AESCAP 2.0 and BWG Invest is further strengthening LIDDS owner structure and it confirms the international interest for LIDDS and the NanoZolid technology.